Metastatic castration-resistant prostate cancer (mCRPC) represents a lethal phase of prostate cancer characterized by disease progression despite ongoing androgen-deprivation therapy (ADT).1,2 Although multiple systemic therapies have demonstrated improvements in radiographic progression-free survival (rPFS) and overall survival (OS), bone metastases remain a dominant driver of morbidity and mortality in this population.2,3 Radium-223 dichloride (Ra223), an alpha-emitting, bone-targeted radiopharmaceutical,…

Metastatic castration-resistant prostate cancer (mCRPC) represents a lethal phase of prostate cancer characterized by disease progression despite ongoing androgen-deprivation therapy (ADT).1,2 Although multiple systemic therapies have demonstrated improvements in radiographic progression-free survival (rPFS) and overall survival (OS), bone metastases remain a dominant driver of morbidity and mortality in this population.2,3 Radium-223 dichloride (Ra223), an alpha-emitting, bone-targeted radiopharmaceutical,…

Metastatic castration-resistant prostate cancer (mCRPC) represents a lethal phase of prostate cancer characterized by disease progression despite ongoing androgen-deprivation therapy (ADT).1,2 Although multiple systemic therapies have demonstrated improvements in radiographic progression-free survival (rPFS) and overall survival (OS), bone metastases remain a dominant driver of morbidity and mortality in this population.2,3 Radium-223 dichloride (Ra223), an alpha-emitting, bone-targeted radiopharmaceutical,…